and data presented at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders conference in Gothenburg, Sweden in March 2023 showed significant improvements in “morning on” symptoms and clinically
and data presented at the International Conference on Alzheimer's and Parkinson's Disease and Related Neurological Disorders conference in Gothenburg, Sweden in March 2023 showed significant improvements in “morning on” symptoms and clinically mea...
Objective: To assess the safety, tolerability, and efficacy of NE3107 in levodopa/carbidopa-treated patients with Parkinson's disease (PD) over 27 days.Background: PD is characterized by the loss of dopaminergic neurons and compromised motor control. Levodopa provides pro-motoric relief but lacks...